Literature DB >> 7714514

Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy.

K M Carroll1, C Nich, B J Rounsaville.   

Abstract

We evaluated treatment response for depressed versus nondepressed ambulatory cocaine abusers in a 12-week randomized controlled trial of desipramine and cognitive-behavioral treatment, alone and in combination. Subjects with depressive symptomatology at baseline tended to have better retention and better cocaine outcomes compared with nondepressed subjects. Desipramine was an effective antidepressant in this sample and was associated with significantly greater reduction in depressive symptoms than was placebo; however, desipramine treatment was not associated with greater reductions in cocaine use for either the depressed or euthymic subgroup. Cognitive-behavioral relapse prevention treatment was associated with significantly longer periods of consecutive abstinence and better retention compared with supportive clinical management for the depressed subgroup, but psychotherapy condition did not have an effect on depressive symptoms. These data point to differential symptom reduction in depressed cocaine addicts and underscore the importance of evaluating combined psychotherapy-pharmacotherapy approaches for this population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7714514     DOI: 10.1097/00005053-199504000-00012

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  12 in total

1.  Pilot study of treatment for major depression among women prisoners with substance use disorder.

Authors:  Jennifer E Johnson; Caron Zlotnick
Journal:  J Psychiatr Res       Date:  2012-06-12       Impact factor: 4.791

Review 2.  Behavioral therapies for co-occurring substance use and mood disorders.

Authors:  Kathleen M Carroll
Journal:  Biol Psychiatry       Date:  2004-11-15       Impact factor: 13.382

Review 3.  The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists.

Authors:  F Ivy Carroll; Roland E Dolle
Journal:  ChemMedChem       Date:  2014-06-30       Impact factor: 3.466

4.  A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients.

Authors:  Wilfrid Noel Raby; Eric A Rubin; Fatima Garawi; Wendy Cheng; Ella Mason; Lisa Sanfilippo; Stephanie Lord; Adam Bisaga; Efrat Aharonovich; Frances Levin; David McDowell; Edward V Nunes
Journal:  Am J Addict       Date:  2013-06-26

5.  Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials.

Authors:  Maryam Bashiri; Michael J Mancino; Virginia A Stanick; Jeff Thostenson; Thomas R Kosten; Alison H Oliveto
Journal:  Am J Addict       Date:  2017-11-08

Review 6.  Psychosocial interventions for psychostimulant misuse.

Authors:  Silvia Minozzi; Rosella Saulle; Franco De Crescenzo; Laura Amato
Journal:  Cochrane Database Syst Rev       Date:  2016-09-29

7.  Cocaine and Psychiatric Symptoms.

Authors:  W Alexander Morton
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-08

8.  Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up.

Authors:  Suzette Glasner-Edwards; Patricia Marinelli-Casey; Maureen Hillhouse; Alfonso Ang; Larissa J Mooney; Richard Rawson
Journal:  J Nerv Ment Dis       Date:  2009-04       Impact factor: 2.254

Review 9.  Development of κ opioid receptor antagonists.

Authors:  F Ivy Carroll; William A Carlezon
Journal:  J Med Chem       Date:  2013-02-14       Impact factor: 7.446

10.  Psychological interventions for co-occurring depression and substance use disorders.

Authors:  Leanne Hides; Catherine Quinn; Stoyan Stoyanov; David Kavanagh; Amanda Baker
Journal:  Cochrane Database Syst Rev       Date:  2019-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.